SKOKIE, Ill., May 12 /PRNewswire/ -- NanoInk, Inc., today announced that the Company’s President and Chief Executive Officer, Dr. Cedric Loiret-Bernal, will be a featured guest speaker at the NanoBusiness Alliance Conference 2006 being held in New York City on May 17 - 19, 2006. The official website for the conference is http://www.nanobusiness2006.com .
(Logo: http://www.newscom.com/cgi-bin/prnh/20060410/NANOLOGO )
Dr. Loiret-Bernal, a leading expert on nanoencryption, will speak about the Company’s Nanoencryption(TM) technology and its use by pharmaceutical customers and will also cover applications for the DPN(R) technology. The presentation will begin at 10:15 a.m. EDT on Wednesday, May 17, 2006, in Salon 1 of the New York Marriott Marquis Times Square located at 1535 Broadway.
Dr. Loiret-Bernal will also host author Katherine Eban at the networking reception to be held that same evening at 6:00 p.m. EDT in the Main Ballroom. Ms. Eban, an investigative medical reporter, will be available to sign copies of her recent book, Dangerous Doses, which examines how counterfeit pharmaceuticals are contaminating America’s drug supply.
Dr. Loiret-Bernal is the former Chief Executive Officer and co-founder of GeneProt, Inc., and has also held many other senior positions in the pharmaceutical and biomedical industries at Abbott Laboratories, Haemonetics, and Porges-Synthelabo. Dr. Loiret-Bernal holds a doctor of medicine degree, summa cum laude, from the University of Bordeaux and has an MBA degree from the J.L. Kellogg School of Management, Northwestern University.
“The NanoBusiness Alliance Conference 2006 offers the opportunity to show the progress made over the past twelve months as NanoInk follows a path towards profitability,” said Dr. Loiret-Bernal. “NanoInk is generating revenues by providing unique solutions to the pharmaceutical and semiconductor industries.”
NanoInk’s proprietary Nanoencryption technology is the one-stop, deeply covert encryption and authentication solution to prevent counterfeit pharmaceuticals from entering the market. Counterfeit pharmaceuticals can be easily identified by the absence of special coded nanoencryption. During the authentication process, illegal products are flagged as mismatches and removed from the supply chain. Using NanoInk’s proprietary technology, pharmaceutical manufacturers and enforcement agencies can identify and significantly reduce counterfeiting and illegal diversion.
About NanoInk(R)
NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN(R), a patented and proprietary nanofabrication technology that allows for unmatched flexibility, accuracy and also its high-resolution Nanoencryption(TM) technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair, and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, and the University of Illinois at Urbana- Champaign. For more information on products and services offered by NanoInk, Inc., see http://www.nanoink.net .
Note: NanoInk and NanoInk logo are registered trademarks owned by
NanoInk, Inc.
Photo: http://www.newscom.com/cgi-bin/prnh/20060410/NANOLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comNanoInk, Inc.
CONTACT: Dileep Gangolli, Investor Relations and Financial Communications,of NanoInk, +1-847-745-3635, ir@nanoink.net
